Joaquim Balsells

Joaquim Balsells

Auto-generated profile, based on publicly available information

Joaquim Balsells

Department of Gastroenterology, Hospital Vall Hebron

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2007 in Transplantation Proceedings
Verified
Journal Article
Closed access
AEA. Escartin
A. Escartin
GSG. Sapisochin
G. Sapisochin
IAItxarone BILBAO AGUIRRE
Itxarone BILBAO AGUIRRE
Ramon VilallongaRamon Vilallonga
Ramon Vilallonga
JBJ. Bueno
J. Bueno
JBJ. Balsells
J. Balsells

1 January 2021 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
ERElizabeth Pando Rau
Elizabeth Pando Rau
PAPiero Alberti
Piero Alberti
RMRodrigo Mata
Rodrigo Mata
MGMaría José Gomez
María José Gomez
LVLaura Vidal
Laura Vidal
RCRamon Charco
Ramon Charco
Background. Changes in BUN have been proposed as a risk factor for complications in acute pancreatitis (AP). Our study aimed to compare changes in BUN versus the Bedside Index for Severity in Acute Pancreatitis (BISAP) score and the Acute Physiology and Chronic Health Evaluation‐II score (APACHE‐II), as well as other laboratory tests such as haematocrit and its variations over 24 h and C‐reactive protein, in order to determine the most accurate test for predicting mortality and severity outcomes in AP. Methods. Clinical data of 410 AP patients, prospectively enrolled for study at our institution, were analyzed. We define AP according to Atlanta classification (AC) 2012. The laboratory test’s predictive accuracy was measured using area‐under‐the‐curve receiver‐operating characteristics (AUC) analysis and sensitivity and specificity tests. Results. Rise in BUN was the only score related to mortality on the multivariate analysis (p = 0.000, OR: 12.7; CI 95%: 4.2−16.6). On the comparative analysis of AUC, the rise in BUN was an accurate test in predicting mortality (AUC: 0.842) and persisting multiorgan failure (AUC: 0.828), similar to the BISAP score (AUC: 0.836 and 0.850) and APACHE‐II (AUC: 0.756 and 0.741). The BISAP score outperformed both APACHE‐II and rise in BUN at 24 hours in predicting severe AP (AUC: 0.873 vs. 0.761 and 0.756, respectively). Conclusion. Rise in BUN at 24 hours is a quick and reliable test in predicting mortality and persisting multiorgan failure in AP patients.

1 August 2017 in Pancreas
Verified
Journal Article
Closed access
MAMaria Teresa Salcedo Allende
Maria Teresa Salcedo Allende
JZJorge Zeron-Medina
Jorge Zeron-Medina
JHJavier Hernandez
Javier Hernandez
TMTeresa Macarulla
Teresa Macarulla
JBJoaquim Balsells
Joaquim Balsells
Santiago Ramo´n y CajalSantiago Ramo´n y Cajal
Santiago Ramo´n y Cajal
Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer. Overexpression of Yes associated protein 1 (YAP1), a downstream target of Hippo pathway, implicated in regulation of cell growth and apoptosis, has been reported in several human tumor types. The objective of this study was to investigate YAP1 expression in patients with PDAC and its prognostic values. Methods: We evaluated YAP1 expression in 64 PDAC and 15 chronic pancreatitis (CP) cases and its related pancreatic intraepithelial neoplasia (PanIN) lesions and in 5 control subjects. Yes associated protein 1 expression was determined by immunohistochemistry. Association of YAP1 with clinicopathologic features in PDAC, disease-free survival, and overall survival was analyzed. Results: We found a higher positive rate of nuclear expression of YAP1 in PDAC than in CP (P = 0.000) and lower expression of YAP1 in PanIN lesions in CP in contrast with expression in PanIN lesions in PDAC. Nuclear overexpression of YAP1 in PDAC is associated with hepatic metastasis (P = 0.0280) and is a prognostic factor (P = 0.0320), as well as surgical margin involvement (P = 0.0013) and tumoral stage (P = 0.0109). Conclusions: Overexpression of YAP1 may occur as a part of tumorigenesis of PDAC. Yes associated protein 1 is an independent prognostic marker for overall survival of PDAC and associated with liver metastasis, being a potential therapeutic target.

1 September 2011 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
MGMañas- Gómez
Mañas- Gómez
MJM. J.
M. J.
RRR. Rodríguez-Revuelto
R. Rodríguez-Revuelto
JBJ. Balsells-Valls
J. Balsells-Valls
JOJ. J. Olsina-Kissler
J. J. Olsina-Kissler
RCRamon Charco
Ramon Charco

24 October 2007 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
IAItxarone BILBAO AGUIRRE
Itxarone BILBAO AGUIRRE
CDCristina Dopazo
Cristina Dopazo
JLJose Luis Lazaro
Jose Luis Lazaro
LCLuis Castells
Luis Castells
AEAlfredo Escartin
Alfredo Escartin
CMCarlos Margarit
Carlos Margarit

1 April 1996 in Journal of Hepatology
Verified
Journal Article
Closed access
RCRamon Charco
Ramon Charco
VVVíctor Vargas
Víctor Vargas
JBJoaquim Balsells
Joaquim Balsells
JLJose Luis Lázaro
Jose Luis Lázaro
EMEnrique Murio
Enrique Murio
CMCarlos Margarit
Carlos Margarit